CEO and Co-Founder
Anne co-founded 23andMe in 2006 after a decade spent in healthcare investing, focused primarily on biotechnology companies. Her hope was to empower consumers with access to their own genetic information and to create a way to generate more personalized information so that commercial and academic researchers could better understand and develop new drugs and diagnostics. Presently, 23andMe has built one of the world’s largest databases of individual genetic information. Its novel, web-based research approach allows for the rapid recruitment of participants to many genome-wide association studies at once, reducing the time and money needed to make new discoveries, and the company has created a proven and standardized resource for finding new genetic association and confirming genetic loci discovered by others. Under Anne’s leadership 23andMe has made significant advances in bringing personalized medicine directly to the public. Anne graduated from Yale University with a BS in Biology. Getting access to and understanding her own genetic information had always been one of her ambitions.
Andy Page brings corporate leadership and deep operational expertise to 23andMe. Andy has been a member of the 23andMe board of directors since 2012 and joined the company as President in 2013. As President, Andy manages all functional areas of the company. In addition, he is responsible for developing the company’s business strategy and identifying opportunities for long-term growth and industry leadership. Before joining 23andMe, Andy served as the President of Gilt Groupe, an online luxury shopping destination, where he oversaw the Company’s various businesses and operations including Women’s, Men’s, Kids & Baby, Home, Park & Bond, Gilt City and Gilt Taste. He joined Gilt in April 2010 as the Chief Financial Officer and transitioned to President in 2011. Prior to joining Gilt, Andy was Chief Operating and Financial Officer at PlayPhone, Inc., where he was responsible for managing the company’s multinational operations. Before PlayPhone, Andy was Chief Financial Officer and SVP of Business Strategy of StubHub Inc. There he managed the company’s financial operations, business strategy, financial reporting, and administrative functions. He led the company’s sale to eBay in 2007. Andy has also held senior executive positions at Panasas Inc., ONI Systems Corp., and Robertson Stephens & Company. Andy holds a BA from Princeton University and a MBA from Harvard Business School. He is an advisor to several private e-commerce companies. He also serves on the board of directors of My New Red Shoes, a nonprofit organization that provides back-to-school clothes for homeless and low-income children in the San Francisco Bay Area.
Vice President, Communications
Angela joined 23andMe in 2014 and brings more than 18 years of communications expertise in the health care, science and technology industries to the company. Angela is responsible for the corporate communications, media relations, investor relations and internal communications activities at 23andMe.
Prior to joining 23andMe, Angela served as vice president of communications and senior media advisor at Intuitive Surgical, the global leader in robotic-assisted surgery. Prior to joining Intuitive Surgical, Angela held senior positions in health care media relations at both Weber Shandwick and Edelman Public Relations. She also served as the chief communications officer at The Cleveland Clinic. Angela began her career in television working in a number of roles including production, community affairs, news, and later in corporate communications for MSNBC and CNBC.
Angela holds a Master of Public Administration from the John F. Kennedy School of Government, Harvard University and a Bachelor of Arts in Communications from the University of California, San Diego.
Vice President, Product
Brad Kittredge is responsible for all elements of the 23andMe user experience, including product vision, design and management. Prior to joining 23andMe, Brad served as director of product management, health at Jawbone. Prior to his tenure at Jawbone, Brad was manager of corporate strategy at McKesson Corp and CEO and founder of ComplexDx, a startup concept focused on solutions to resolve complex medical cases by connecting patients and physicians. Brad holds an MBA from the Walter A. Haas School of Business; a Master’s degree in Public Health Management, Health Policy from the University of California, Berkeley; a Master’s in International Affairs from the University of California, San Diego and a Bachelor’s degree in Psychology from the University of California, Berkeley.
Chief Financial Officer & Head of Operations
Dean joined 23andMe in 2015 as chief financial officer and head of operations responsible for 23andMe’s global financial and clinical laboratory operations.
Most recently, Dean served as the chief financial officer for Adaptive Biotechnologies, where he lead all financial operations as well as laboratory operations and facilities management. Prior to his role at Adaptive Biotechnologies, Dean spent 13 years at Genomic Health, where he served as both vice president of operations and chief financial officer. Dean also founded a successful CPA and consulting firm that he led for nearly a decade.
Dean holds a Bachelor of Science degree in Business Administration from the University of California, Berkeley, and a Master of Science in Taxation from Golden Gate University. He is a Certified Public Accountant.
Jill Hagenkord, MD
Chief Medical Officer
Dr. Jill Hagenkord joined the company in 2014 and serves as chief medical officer for 23andMe where she is responsible for all medical affairs activities serving as the company liaison to physician, medical, genetics and research industry groups. Jill also oversees laboratory, shipping and fulfillment operations for the company.
Previously, Jill served as senior vice president of medical strategy for InVitae Corporation, a genetics information company, where her role included serving as medical director, contributing to corporate strategy, acting as commercial liaison, and leading the company’s physician education programs.
Jill is a board-certified molecular genetic pathologist. Prior to joining Invitae, she served as chief medical officer and senior vice president at Complete Genomics, Inc. Her other prior experiences include founder and chief medical officer for iKaryos Diagnostics, associate professor of pathology at Creighton University School of Medicine, director of molecular pathology and clinical genomics at Creighton Medical Laboratories, and pathologist at Deltagen, Inc. Jill received her M.D. from Stanford University School of Medicine in 1999, did her residency training in pathology at the University of California at San Francisco and the University of Iowa, and completed fellowships in pathology/oncology informatics and molecular genetic pathology at the University of Pittsburgh Medical Center.
Vice President, International
Jonathan Ward joined 23andMe in 2012 and currently serves as Vice President, International, with responsibility for growing the company’s international operations, including consumer offerings and strategic business opportunities. Prior to joining 23andMe, Jonathan served most recently as interim Chief Marketing Officer at eHarmony.com and held a variety of marketing and business development roles during his eight-year tenure there. Jonathan has also held marketing and business development roles at America Online. Prior to AOL, Jonathan was a management consultant with McKinsey & Company, and an associate at Ogilvy, Adams & Rinehart. Jonathan has a bachelor of arts degree in English from Williams College and holds a master’s in management from the J.L. Kellogg School of Management at Northwestern University.
Chief Legal and Regulatory Officer
Kathy Hibbs, Esq. joined 23andMe as Chief Legal and Regulatory Officer in 2014. Kathy brings more than 20 years of legal and management expertise in the clinical laboratory and medical device industries to 23andMe. Prior to joining 23andMe, Kathy served as senior vice president and general counsel, responsible for the legal, regulatory and business development functions at Genomic Health, Inc. Kathy has also held related posts at Monogram Biosciences Inc., and Varian Medical Systems, Inc.. Kathy is active in several industry groups including the American Clinical Laboratory Association (ACLA), the Coalition for 21st Century Medicine and the Personalized Medicine Coalition (PMC). Kathy holds a Juris Doctorate from the University of California, Hastings School of Law, and a Bachelors of Arts in Political Science, from the University of California, Riverside.
Vice President, Marketing
Neil Rothstein is responsible for the marketing, branding and customer acquisition activities of the company. Prior to joining 23andMe, Neil worked at Netflix for 11 years most recently serving as VP, Online Marketing where he led the company’s global online marketing activities across the US, Canada, Latin America, UK, and Ireland. Neil has also had roles with RateItAll, ESPN, and the Atlanta Committee for the Olympic Games. Neil received an MBA from the Gouizueta Business School at Emory University and a BA in Economics from Brandeis University.
Richard Scheller, PhD
Chief Science Officer & Head of Therapeutics
Dr. Richard Scheller joined 23andMe in 2015 as chief science officer and head of the newly formed therapeutics group. In his role, Dr. Scheller is responsible for building a dedicated research and development team that will use human genetic data as the starting point for identifying new therapies for both common and rare diseases.
Prior to 23andMe, Dr. Scheller retired from a 14-year career at Genentech where he served as executive vice president of research and early development. Dr. Scheller also served on the faculty of Stanford University for 19 years as a professor in the Department of Biological Sciences and the Department of Molecular and Cellular Physiology and was an investigator at the Howard Hughes Medical Institute of Stanford University Medical Center.
In 2013, Dr. Scheller received the Albert Lasker Basic Medical Research Award, often referred to as “America’s Nobels,” for discoveries concerning the molecular machinery and regulatory mechanism that underlie the rapid release of neurotransmitters. He has published more than 280 research studies.
Dr. Scheller is a member of the American Academy of Arts & Sciences and the National Academy of Sciences. He also currently serves on the Board of Trustees for the California Institute of Technology.
Dr. Scheller holds a Bachelor of Science in Biochemistry from University of Wisconsin-Madison and a Ph.D. in Chemistry from the California Institute of Technology. He was a postdoctoral fellow in the Division of Biology at the California Institute of Technology and a postdoctoral fellow in Molecular Neurobiology at Columbia University at the College of Physicians and Surgeons.
Robert Gentleman, PhD
Vice President, Computational Biology
Dr. Robert Gentleman joined 23andMe in 2015 as vice president of computational biology. In this role, he focuses on the exploration of how human genetic and trait data in the 23andMe database can be used to identify new therapies for disease. Dr. Gentleman will specifically focus on collaborating with Dr. Richard Scheller and the recently formed therapeutics group.
Most recently, Dr. Gentleman served as Senior Director of Bioinformatics and Computational Biology at Genentech. Prior to this role, he was head of the computational biology department at the Fred Hutchinson Cancer Research Center. Dr. Gentleman served as a professor at Harvard University, the University of Auckland, and the University of Waterloo.
He has been awarded the Benjamin Franklin Award, a recognition for Open Access in the Life Sciences presented by the Bioinformatics Organization and is Fellow of the International Society for Computational Biology (ISCB). Dr. Gentleman, along with Ross Ihaka at the University of Auckland, is also recognized as one of the originators of the R programming language, a widely-used programming language software environment for statistical computing and graphics. Dr. Gentleman was one of the founders of the Bioconductor Project.
Dr. Gentleman earned a Bachelor of Science in Mathematics from The University of British Columbia and holds a Doctor of Philosophy, Ph.D., in Statistics from the University of Washington.
Vice President, Commercial Marketing
Ruby joined 23andMe to lead the company’s global commercial marketing efforts and expand collaboration with industry and academic institutions, as well as to create more business-to-business partnerships. She has a wealth of experience commercializing genomics internationally, having worked for a variety of notable biotech companies. Before joining 23andMe, Ruby served as the head of marketing and commercial development at Invitae Corporation, a genetic information company. Prior to her work there, she worked at Affymetrix, Inc., where she headed international marketing and clinical development. Earlier in her career, Ruby also worked with other genomics companies including Life Technologies, Dharmacon and AbGene. A native of the UK, Ruby holds a Bachelor of Science in Molecular Biology from the University College London.
Vice President, Engineering
Steve joined 23andMe in 2010 and is responsible for engineering. Prior to 23andMe, Steve was VP of engineering at Loopt and co-founder and VP of technology at Glimpse.com (acquired by TheFind.com). Earlier Steve served as the VP of engineering for Consumer Products and Solutions at Symantec and headed the engineering team at Cendura (acquired by CA), growing development and QA teams in both the U.S. and India. He also served as the SVP and GM of the Internet Portal Division for Healtheon/WebMD (IPO: HLTH), where he operated worldwide engineering and business teams and drove M&A technology integration. He holds three U.S. patents in the area of Object Oriented Operating System Technology. Steve received a BS in Computer Science from The Ohio State University.